Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fujian Haixi Pharmaceuticals Co's EBIT per Share for the
six
months ended in Dec. 2025 was HK$3.24.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$3.24.
During the past 12 months, the average EBIT per Share Growth Rate of Fujian Haixi Pharmaceuticals Co was 64.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 39.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Fujian Haixi Pharmaceuticals Co's EBIT per Share or its related term are showing as below:
HKSE:02637'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 39.7 Med: 39.7 Max: 39.7
Current: 39.7
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Fujian Haixi Pharmaceuticals Co was 39.70% per year. The lowest was 39.70% per year. And the median was 39.70% per year.
HKSE:02637's 3-Year EBIT Growth Rate is ranked better than 84.34% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs HKSE:02637: 39.70
Fujian Haixi Pharmaceuticals Co (HKSE:02637) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Fujian Haixi Pharmaceuticals Co EBIT per Share Related Terms
Fujian Haixi Pharmaceuticals Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co EBIT per Share Chart
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$3.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a EBIT per Share of HK$3.24 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. According to the industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #127 out of 811 companies in the Drug Manufacturers industry, placing it in the top 15.7%.
Is Fujian Haixi Pharmaceuticals Co's EBIT per Share too high?
Fujian Haixi Pharmaceuticals Co's current EBIT per Share is HK$3.24. Based on the distribution chart, Fujian Haixi Pharmaceuticals Co ranks #127 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #127 out of 811 companies for EBIT per Share. This places Fujian Haixi Pharmaceuticals Co in the top 16% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fujian Haixi Pharmaceuticals Co's current EBIT per Share is HK$3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current EBIT per Share of HK$3.24. The current EBIT per Share is HK$3.24. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current EBIT per Share is HK$3.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score
Get the complete analysis for HKSE:02637
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02637 has been successfully added to your 
